Comparative Pharmacology
Head-to-head clinical analysis: THEOBID JR versus THEOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOBID JR versus THEOVENT.
THEOBID JR. vs THEOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits phosphodiesterase, increasing intracellular cAMP; causes bronchodilation, central nervous system stimulation, and positive inotropic/chronotropic effects.
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular cAMP levels, and by antagonizing adenosine receptors.
300 mg orally every 12 hours, extended-release tablet. Titrate to serum theophylline concentration of 5-15 mcg/mL.
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
None Documented
None Documented
3-8 hours in adults; prolonged in neonates, cirrhosis, heart failure (up to 30 hours). Tobacco smoking induces clearance (half-life 4-5 hours).
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Hepatic metabolism (90%), renal excretion of unchanged drug (10%). Metabolites excreted in urine.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator